Viatris 2023 Sustainability Report: Continued Innovation for Infectious Disease
Viatris' 2023 Sustainability Report highlights significant progress in combatting infectious diseases like HIV, TB, malaria, and hepatitis. Viatris has expanded access to high-quality HIV/AIDS treatment, including self-testing diagnostics, pediatric therapies, and innovative formulations. In 2023, Viatris developed a dual oral pill for HIV and birth control with the Bill and Melinda Gates Foundation, targeting WHO approval by end-2024. The company also partnered with DNDi for slow-release flucytosine to treat cryptococcal meningitis.
Viatris supports local ARV manufacturing and engages in licensing agreements with organizations like Gilead and Viiv Healthcare. Over 32% of people on HIV treatment globally use Viatris products. In India, Viatris launched a single pill HIV treatment reaching 4,000 patients in six months. The company offers more than 700 infectious disease product registrations across LMICs.
In the fight against TB, Viatris introduced pretomanid for multidrug-resistant strains, approved in 57 countries. Efforts also extend to hepatitis B and C, with notable initiatives in the Philippines, Myanmar, and Bulgaria. Viatris' partnerships and innovative solutions aim to meet its goal of providing ARV therapy to 30 million patients by 2025.
Il Rapporto sulla Sostenibilità 2023 di Viatris evidenzia progressi significativi nella lotta contro le malattie infettive come HIV, TB, malaria e epatite. Viatris ha ampliato l'accesso a trattamenti di alta qualità per HIV/AIDS, inclusi diagnostic da autodiagnosi, terapie pediatriche e formulazioni innovative. Nel 2023, Viatris ha sviluppato una pillola orale duale per HIV e contraccezione in collaborazione con la Bill e Melinda Gates Foundation, puntando all'approvazione dell'OMS entro la fine del 2024. L'azienda ha anche collaborato con DNDi per la flucitosina a rilascio controllato per il trattamento della meningite criptococcica.
Viatris sostiene la produzione locale di ARV e intraprende accordi di licenza con organizzazioni come Gilead e Viiv Healthcare. Oltre il 32% delle persone in trattamento per HIV a livello globale utilizza i prodotti di Viatris. In India, Viatris ha lanciato un trattamento HIV in una pillola singola che ha raggiunto 4.000 pazienti in sei mesi. L'azienda offre oltre 700 registrazioni di prodotti per malattie infettive nei PAISM.
Nella lotta contro la TB, Viatris ha introdotto il pretomanid per ceppi multi-resistenti, approvato in 57 paesi. Gli sforzi si estendono anche all'epatite B e C, con iniziative significative nelle Filippine, in Myanmar e in Bulgaria. Le partnership e le soluzioni innovative di Viatris mirano a raggiungere l'obiettivo di fornire terapia ARV a 30 milioni di pazienti entro il 2025.
El Informe de Sostenibilidad 2023 de Viatris destaca avances significativos en la lucha contra enfermedades infecciosas como el VIH, la TB, la malaria y la hepatitis. Viatris ha ampliado el acceso a tratamientos de calidad para VIH/SIDA, incluyendo diagnósticos de autoprueba, terapias pediátricas y formulaciones innovadoras. En 2023, Viatris desarrolló una píldora oral dual para el VIH y el control de la natalidad en asociación con la Fundación Bill y Melinda Gates, con el objetivo de obtener la aprobación de la OMS para finales de 2024. La compañía también se asoció con DNDi para la flucitosina de liberación lenta para tratar la meningitis criptocócica.
Viatris apoya la producción local de ARV y se involucra en acuerdos de licencias con organizaciones como Gilead y Viiv Healthcare. Más del 32% de las personas que reciben tratamiento para el VIH a nivel mundial utilizan productos de Viatris. En India, Viatris lanzó un tratamiento de VIH en una sola píldora que alcanzó a 4,000 pacientes en seis meses. La compañía ofrece más de 700 registros de productos para enfermedades infecciosas en los PAISM.
En la lucha contra la TB, Viatris introdujo el pretomanid para cepas multirresistentes, aprobado en 57 países. Los esfuerzos también se extienden a las hepatitis B y C, con iniciativas notables en Filipinas, Myanmar y Bulgaria. Las asociaciones y soluciones innovadoras de Viatris tienen como objetivo cumplir con su meta de proporcionar terapia ARV a 30 millones de pacientes para 2025.
Viatris의 2023 지속 가능성 보고서는 HIV, TB, 말라리아 및 간염과 같은 전염병 퇴치에서 중요한 진전을 강조합니다. Viatris는 자가 검사 진단, 소아 치료 및 혁신적인 제형을 포함하여 고품질 HIV/AIDS 치료에 대한 접근을 확대했습니다. 2023년, Viatris는 Bill & Melinda Gates 재단과 협력하여 HIV 및 피임을 위한 복합 경구 약물을 개발했으며, 2024년 말까지 WHO 승인을 목표로 하고 있습니다. 이 회사는 또한 암피실린에 대한 느린 방출 플루시토신을 위해 DNDi와 협력했습니다.
Viatris는 지역 ARV 제조를 지원하며 Gilead 및 Viiv Healthcare와 같은 조직과 라이센스 계약을 체결합니다. 전 세계적으로 HIV 치료를 받고 있는 사람의 32% 이상이 Viatris 제품을 사용하고 있습니다. 인도에서 Viatris는 6개월 만에 4,000명의 환자에게 도달한 단일 정제 HIV 치료제를 출시했습니다. 이 회사는 LMICs 전역에서 700개 이상의 감염병 제품 등록을 제공합니다.
TB와의 싸움에서 Viatris는 다제내성 균주에 대한 프레토마니드를 도입했으며, 57개국에서 승인되었습니다. 노력은 필리핀, 미얀마 및 불가리아에서 주목할 만한 이니셔티브의 간염 B 및 C로도 확장됩니다. Viatris의 파트너십과 혁신적인 솔루션은 2025년까지 3천만 명의 환자에게 ARV 치료를 제공하기 위한 목표를 달성하는 것을 목표로 하고 있습니다.
Le Rapport de Durabilité 2023 de Viatris souligne des progrès significatifs dans la lutte contre les maladies infectieuses telles que le VIH, la tuberculose, le paludisme et l'hépatite. Viatris a élargi l'accès à des traitements de haute qualité pour le VIH/SIDA, y compris des diagnostics d'autotest, des thérapies pédiatriques et des formulations innovantes. En 2023, Viatris a développé un comprimé oral à double action pour le VIH et la contraception en collaboration avec la Fondation Bill et Melinda Gates, visant l'approbation de l'OMS d'ici fin 2024. L'entreprise a également collaboré avec DNDi pour la flucytosine à libération lente afin de traiter la méningite cryptococcique.
Viatris soutient la fabrication locale d'ARV et engage des accords de licence avec des organisations telles que Gilead et Viiv Healthcare. Plus de 32 % des personnes sous traitement VIH dans le monde utilisent des produits Viatris. En Inde, Viatris a lancé un traitement du VIH sous forme de comprimé unique qui a atteint 4 000 patients en six mois. L'entreprise propose plus de 700 enregistrements de produits pour les maladies infectieuses dans les PMA.
Dans la lutte contre la TB, Viatris a introduit le prétomanid pour les souches multirésistantes, approuvé dans 57 pays. Les efforts s'étendent également à l'hépatite B et C, avec des initiatives notables aux Philippines, en Birmanie et en Bulgarie. Les partenariats et solutions innovantes de Viatris visent à atteindre l'objectif de fournir un traitement ARV à 30 millions de patients d'ici 2025.
Der Nachhaltigkeitsbericht 2023 von Viatris hebt bedeutende Fortschritte im Kampf gegen Infektionskrankheiten wie HIV, TB, Malaria und Hepatitis hervor. Viatris hat den Zugang zu hochwertigen HIV/AIDS-Behandlungen erweitert, einschließlich Selbsttests, pädiatrischen Therapien und innovativen Formulierungen. Im Jahr 2023 entwickelte Viatris in Zusammenarbeit mit der Bill und Melinda Gates Stiftung eine duale orale Pille für HIV und Verhütung, die bis Ende 2024 die Zustimmung der WHO anstrebt. Das Unternehmen hat zudem mit DNDi zusammengearbeitet, um die langsame Freisetzung von Flucytosin zur Behandlung der kryptokokken Meningitis zu ermöglichen.
Viatris unterstützt die lokale ARV-Herstellung und engagiert sich in Lizenzvereinbarungen mit Organisationen wie Gilead und Viiv Healthcare. Über 32 % der weltweit in HIV-Behandlung befindlichen Personen verwenden Produkte von Viatris. In Indien brachte Viatris eine HIV-Behandlung in einer einzigen Pille auf den Markt, die innerhalb von sechs Monaten 4.000 Patienten erreichte. Das Unternehmen bietet mehr als 700 Produktregistrierungen für Infektionskrankheiten in den LMICs an.
Im Kampf gegen TB führte Viatris Pretomanid für multiresistente Stämme ein, das in 57 Ländern genehmigt wurde. Die Bemühungen erstrecken sich auch auf Hepatitis B und C mit bemerkenswerten Initiativen auf den Philippinen, in Myanmar und in Bulgarien. Die Partnerschaften und innovativen Lösungen von Viatris zielen darauf ab, bis 2025 ARV-Therapie für 30 Millionen Patienten bereitzustellen.
- None.
- None.
NORTHAMPTON, MA / ACCESSWIRE / September 4, 2024 / Increased availability of testing and antiretrovirals has led to global progress in preventing and managing infectious diseases like HIV, tuberculosis (TB), malaria and hepatitis in the last quarter of a century. However, progress is slower in some low- and middle-income countries (LMICs) where the needs are greatest, especially among more vulnerable groups like women and children. In addition, the COVID-19 pandemic, continuing emergence of antimicrobial resistance (AMR) and growing impacts from climate change have demonstrated how infectious threats can emerge and have devastating global effects.
At Viatris, we have expanded access at scale to high-quality HIV/AIDS treatment for more than a decade. Our work includes helping to prevent HIV infections, increasing diagnosis and treatment and providing healthcare solutions. We also are working on local manufacturing initiatives with partners to transfer technology to expand access where it is most needed. Over the years, we have continued to seek improvements to existing molecules to better meet patient needs, including introducing novel heat-stable generic formulations, more convenient packaging options and pediatric therapies as well as extended shelf life for certain products.
Number of countries to which we provide access to high-quality and affordable ARVs ~125
Percentage of people on treatment for HIV that use a Viatris product1 ~
32%
Viatris has worked to provide in-vitro HIV rapid diagnostic tests for self-testing in LMICs, and during 2023, we continued work to develop a dual oral pill for HIV and birth control in collaboration with the Bill and Melinda Gates Foundation and the Children's Investment Fund Foundation. The product is expected to be filed with the WHO PQ approval by the end of 2024. All the above are important components to make progress on the collective goals of preventing HIV infections, expanding treatment and providing healthcare solutions to people living with HIV.
During 2023, we continued our partnership with the international, not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) for the development of flucytosine slow-release formulation, a drug used for the treatment of cryptococcal meningitis, with the intention to reduce the pill burden and increase treatment adherence.
As part of our strategy to expand access to ARV treatments, we are working with international organizations for pooled procurement, engaging in licensing agreements with originator pharmaceutical companies and the Medicines Patent Pool and participating in government tenders. We provide a single price for all applicable countries supplied via leading global procurement mechanisms, The Global Fund to Fight AIDS, TB and Malaria, and the U.S. PEPFAR Program.
Viatris has eight licensing agreements with the Medicines Patent Pool (MPP) for HIV - including PrEP - hepatitis C and COVID-19. For ARV and infectious disease products, Viatris also has license agreements with Gilead, Viiv Healthcare, MSD, TB Alliance and Otsuka.
Product registrations are an important part of enabling access to patients across geographies. We consistently file our ARV treatments with the U.S. FDA and the WHO Prequalification pathways to enable procurement by PEPFAR, the Global Fund to Fight AIDS, TB and Malaria, as well as other international agencies. Still, many countries require local registration in addition to these global approvals. To meet this need, we have steadily been filing for local market authorizations of our ARV products based on country guidelines across all key high-burden HIV countries.2
Viatris files all relevant ARV products based on country guidelines across key high-burden HIV countries. We have more than 700 registrations of infectious disease products across LMICs.
In 2023, Viatris engaged with WHO to seek scientific advice for regulatory approval of two different medicines improving on existing molecules to better meet needs of people living with and at risk for HIV, building on our long legacy of making relevant improvements in these medicines. In 2023, the shift to consolidate treatments for patients using ARVs continued, meaning that most of the HIV programs across LMICs transitioned to a dolutegravir-based regimen across first-line, second-line and pediatric populations.
Despite significant progress made over the years, the burden of HIV remains high in many countries. Estimates indicate that around 2.47 million people in India are living with HIV.3 Viatris has been a trusted partner to the government over several years in supplying HIV medicines and in 2023, Viatris launched in India a single pill combination HIV treatment of tenofovir alafenamide, emtricitabine and dolutegravir, reaching more than 4,000 patients in the first six months it was available.
In the last two years, Viatris has launched more than 10 new ARVs in South Africa, including a darunavir/ritonavir combination used for difficult-to-treat HIV patients when initial treatments have failed or not been tolerated, as well as the first fixed-dose tenofovir alafenamide combination to be available in South Africa. This has provided patients living with HIV increased access to leading treatments, helping to improve HIV outcomes in the country and contributing to the fight against HIV.
Improving Treatment for Children Living with HIV
Protecting and improving the health of children is a fundamental global health priority. Although significant strides have been made, there are still major disparities globally, with children in LMICs being among the most vulnerable. Complexities around formulations and dosage guidelines can often be hurdles to children accessing the care they need.
We have built strong partnerships with multiple stakeholders to improve access to ARVs, with particular attention to vulnerable populations like children. For example, in partnership with Viiv Healthcare and the Clinton Health Access Initiative (CHAI), Viatris has worked to develop a dispersible form of treatment which will reduce the pill burden in pediatric populations, which hopefully will significantly improve the treatment experience for children living with HIV.
Viatris has more than 150 medicines in the 2023 Essential Medicines List for Children. This represents more than
40% of the total list.Viatris has more than
45% of the anti-infective medicines in the Essential Medicines List for Children.Approximately
65% of children on treatment for HIV use a Viatris product.4
In 2023, we received approval of a single tablet regimen - the fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg - that will reduce the pill burden for children living with HIV.
In South Africa, we provided access to leading fixed-dose combinations for children living with HIV by launching Dumiva dispersible and dolutegravir dispersible in 2023, which enable caregivers to provide easy-to-administer medication to children as opposed to syrups that can be difficult for some children to take.
These milestones support the company's sustainability goal to provide ARV therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.
The Power of Partnerships in Treating TB
Our work in infectious disease also includes a focus on TB, one of the leading causes of infectious disease deaths worldwide.5 In many cases, TB can be cured with an antibiotic treatment regimen for six months; however, non-adherence is a challenge for TB control and prevention programs. Non-adherence to TB treatment increases the risk of morbidity and mortality and fuels drug resistance, impacting both individuals and communities.
Through our continued partnerships, Viatris has launched pretomanid, specifically approved for adults with multidrug-resistant TB (MDR-TB). It's only the third new anti-TB drug approved in the past half-century. It was developed by TB Alliance, a nonprofit organization that develops and delivers new TB treatments.
In 2023, we completed another 57 registrations for pretomanid, and we are awaiting approval in 10 countries, spanning across multiple continents and income levels.
Partnerships like the one with TB Alliance are essential to providing more sustainable access to medicine. Pretomanid reached patients in more than 40 countries in 2023.
Continuing Our Commitment to Prevent and Treat Hepatitis
Hepatitis is an inflammation of the liver that is caused by a variety of infectious viruses and noninfectious agents leading to a range of health problems, some of which can be fatal. For examples, types B and C lead to chronic disease in hundreds of millions of people and together are the most common cause of liver cirrhosis, liver cancer and viral hepatitis-related deaths. It's estimated that more than 350 million people worldwide live with hepatitis B or C, and for many, testing and treatment are out of reach.6 We have a long tradition of helping to address hepatitis B and C, both through awareness and prevention and in making treatment more available.
Fighting TB in India
India leads the world in TB cases, a stark statistic that caused the government to set an aggressive target to eliminate TB in India by 2025.3 As many as 45,000 people are being treated for MDR TB in India. More than 10,000 of those patients were treated with a Viatris product, delamanid, in 2023. Viatris supplied this medicine through participation in a government tender and through India's first order through the Global Drug Facility of the Stop TB Partnership, an innovative public-private partnership.
Examples from our work in 2023 include:
In the Philippines, a partnership with PHILUSA we offered a lower priced product to patients living with hepatitis B.
In Myanmar, in collaboration with Burnet Institute, nearly 800 hepatitis C patients were treated with MyHepDVIR at a subsidized price. This marked one of the largest treatment initiatives ever conducted for hepatitis C in Myanmar, a country that carries a disease burden of 1.3 million people living with hepatitis C.
Collaborated in Bulgaria with the patient organization HepActive to raise awareness of hepatitis B risk factors, diagnosis and treatment adherence and to provide psychological support to patients diagnosed with hepatitis B through webinars and social media campaign.
View the full 2023 Sustainability Report.
Sources
1 Excludes the U.S., EU and other developed markets. Also excludes Russia, China and Mexico, where we do not commercialize ARVs
2 WHO Global List of High Burden Countries
3 India HIV Estimates Report
4 Excludes the U.S., EU and other developed markets. Also excludes Russia, China and Mexico, where we do not commercialize ARVs.
5 WHO Tuberculosis Fact Sheet
6 WHO Hepatitis Fact Sheet
View additional multimedia and more ESG storytelling from Viatris on 3blmedia.com.
Contact Info:
Spokesperson: Viatris
Website: https://www.3blmedia.com/profiles/viatris
Email: info@3blmedia.com
SOURCE: Viatris
View the original press release on accesswire.com
FAQ
What does Viatris' 2023 Sustainability Report highlight?
How has Viatris impacted HIV treatment globally?
What new products did Viatris launch in India in 2023?
What are Viatris' recent achievements in treating TB?
How is Viatris addressing hepatitis B and C?
